Unlock the full potential of RNA therapeutics with our comprehensive mRNA Delivery Platform. We provide multi-modal delivery solutions—including lipid nanoparticles (LNPs), polymer-based carriers, liposomes, exosomes, viral-like particles, RNA nanostructures, and next-generation hybrid systems—engineered to achieve precise cellular uptake, high expression efficiency, and optimized biodistribution. From carrier design and formulation optimization to in-vitro testing, in-vivo validation, and scalable manufacturing support, we deliver end-to-end services that accelerate your mRNA programs with unmatched speed, scientific rigor, and technical depth.
mRNA Delivery Technology(LNPs, Liposomes, Ionizable Lipids)
Services We Provide:
Advantages:
Services We Provide:
Advantages:
Services We Provide:
Advantages:
Services We Provide:
Advantages:
(RNA Origami, Aptamer-Directed Systems)
Services We Provide:
Advantages:
(Lipid-Polymer, Lipid-Protein, Polymer-Exosome)
Services We Provide:
Advantages:
(Electroporation, Microinjection, Needle-Free Delivery)
Services We Provide:
Advantages:
(For partners seeking cutting-edge or proprietary solutions)
Services We Provide:
Advantages:
| Delivery Platform | Best Use Cases | Strengths | Limitations | Formulation Services We Provide | Targeting Options | In-Vitro Capabilities | In-Vivo Capabilities | Scalability / GMP Readiness |
| Lipid-Based Systems (LNPs, Liposomes) | Vaccines, gene editing, systemic delivery | High efficiency, clinically validated, strong endosomal escape | Potential inflammation, liver-biased targeting | Custom LNP formulation, microfluidic production, lipid screening | Ligands, peptides, antibodies, lipid tuning | Uptake, potency, protein expression assays | Biodistribution, PK/PD, safety studies | Excellent; industry standard |
| Polymer-Based Systems | Tumor targeting, lung delivery, large/modified mRNA | Highly tunable, low immunogenicity, PEG-free | Complex optimization, variable in vivo efficiency | Polymer synthesis, polyplex design, release control, stability optimization | Receptor ligands, peptides, aptamers | Transfection, endosomal escape, expression assays | Lung/tumor/muscle targeting models | Good; chemistry scalable |
| Exosomes / Extracellular Vesicles (EVs) | CNS delivery, oncology, immune modulation | Crosses BBB, natural, low toxicity | Lower loading efficiency, complex purification | EV isolation, mRNA loading, surface engineering, stability optimization | Engineered ligands, glycoproteins | Potency in neuronal/tumor/immune cells | CNS/tumor targeting, tropism validation | Moderate; improves with bioreactor scale |
| Viral-Like Particles (VLPs) | Immuno-oncology, APC targeting | High uptake, strong tropism, robust mRNA expression | More immunogenic, complex to produce | VLP assembly, mRNA packaging, nanocage design | Viral ligands, glycoproteins | APC-targeted assays, expression validation | Immune profiling, tumor models | Good; established VLP production workflows |
| RNA Nanostructures | Precision oncology, receptor-specific delivery | Fully programmable, biocompatible | Early-stage, stability challenges | RNA nanostructure design, aptamer targeting | Sequence-guided targeting | Uptake/expression confirmation | Receptor-specific targeting | Emerging scalability |
| Hybrid Nanoparticle Systems | Complex indications, co-delivery | Combines strengths of multiple technologies | More complex to optimize | Hybrid design, co-formulation, controlled release | Ligands, peptides, multi-target | Multi-payload potency assays | Broad biodistribution profiling | Good; depends on material |
| Peptide / CPP Delivery | Local delivery, ex vivo engineering | Efficient penetration, tunable, safe | Lower stability in vivo | Peptide–mRNA complexes, peptide screening | Targeting peptides, receptor motifs | Uptake, cytotoxicity, potency assays | Local or systemic delivery validation | Moderate; peptide synthesis scalable |
| Physical Delivery (Electroporation, Microinjection) | Ex vivo cell therapy, embryos | High efficiency, bypasses endosomal escape | Not suitable for systemic use | Electroporation optimization, ex vivo workflows | N/A | High-throughput electroporation screens | Ex vivo CAR-T, NK, HSC mRNA delivery | N/A for GMP drug product |
We define:
High-throughput screening of:
Optimized for efficacy, stability, and toxicity profile.
While most providers rely on a single delivery system (usually LNP), we offer a true multi-modality approach, including:
You are not limited by a single technology. We help you find the system that works best for your indication.
We maintain a diverse, continuously expanding library of:
This allows rapid screening and optimization to achieve:
Unlike conventional CROs or material suppliers, we offer a fully integrated, end-to-end service platform：
We support:
Whether you need:
We provide flexible support tailored to the specific requirements of your project.
We emphasize:
Your delivery system is not a black box—we turn it into a scientifically validated platform.
(CAR-T, NK, HSC and iPSC Programs)
Connect with our scientific team to evaluate your goals, explore tailored delivery strategies, review feasibility options, or request a detailed proposal designed around your timeline and payload requirements. Whether you are optimizing an existing formulation or building a multi-modal delivery solution from the ground up, we provide the technical insight, data-driven guidance, and flexible support needed to move your program forward with confidence. Your breakthrough deserves a delivery system engineered for precision, performance, and scalability—let us help you build it.
